<DOC>
	<DOCNO>NCT01480063</DOCNO>
	<brief_summary>The primary objective study collect additional safety data include incidence rate seizure specific Adverse Events ( AEs ) interest participant take Fampyra routine clinical practice . The secondary objective study characterize utilization pattern Fampyra routine clinical practice , ass effectiveness risk minimization measure describe risk management plan Fampyra , assess change time participant self-reported evaluation physical psychological impact Multiple Sclerosis ( MS ) take Fampyra ass change time physician assessment walk ability participant take Fampyra ( MS participant ) .</brief_summary>
	<brief_title>An Observational Study Collect Information Safety Document Drug Utilization Fampyra ( BIIB041 ) When Used In Routine Medical Practice</brief_title>
	<detailed_description />
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>4-Aminopyridine</mesh_term>
	<criteria>Key MS patient disease subtype â‰¥18 year age must newly prescribe Fampyra yet start treatment . Patients willing able provide write informed consent . Key NOTE : Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>